Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2014; 5(6): 854-859
Published online Dec 15, 2014. doi: 10.4239/wjd.v5.i6.854
Published online Dec 15, 2014. doi: 10.4239/wjd.v5.i6.854
Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes
Nasser Mikhail, Department of Medicine, Endocrine Division, OliveView-UCLA Medical Center, Sylmar, CA 91342, United States
Author contributions: Mikhail N solely contributed to this paper.
Correspondence to: Nasser Mikhail, MD, MSc, Department of Medicine, Endocrine Division, OliveView-UCLA Medical Center, 14445 Olive View Dr, Sylmar, CA 91342, United States. nmikhail@dhs.lacounty.gov
Telephone: +1-310-2607897
Received: July 2, 2014
Revised: July 19, 2014
Accepted: August 27, 2014
Published online: December 15, 2014
Processing time: 163 Days and 19.4 Hours
Revised: July 19, 2014
Accepted: August 27, 2014
Published online: December 15, 2014
Processing time: 163 Days and 19.4 Hours
Core Tip
Core tip: Sodium-glucose co-transporter type 2 inhibitors are recently approved drugs for type 2 diabetes with unique mechanism of action. In this minireview, the author provides a practical approach on how to select the best candidates for these drugs.